Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 485

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 485
---
 summary is qualified in its entirety by reference to the 2023 Omnibus Plan attached as an exhibit to the
registration statement of which this Annual Report forms a part.

Administration

The
2023 Omnibus Plan is administered by our board of directors or our compensation committee, or any other committee or subcommittee or
one or more of our officers to whom authority has been delegated (collectively, the “Administrator”). The Administrator has
the authority to interpret the 2023 Omnibus Plan and award agreements entered into with respect to the 2023 Omnibus Plan; to make, change
and rescind rules and regulations relating to the 2023 Omnibus Plan; to make changes to, or reconcile any inconsistency in, the 2023
Omnibus Plan or any award agreement covering an award; and to take any other actions needed to administer the 2023 Omnibus Plan.

Eligibility

The
Administrator may designate any of the following as a participant under the 2023 Omnibus Plan: any officer or employee, or individuals
engaged to become an officer or employee, of our company or our affiliates; and consultants of our company or our affiliates, and our
directors, including our non-employee directors.

Types
of Awards

The
2023 Omnibus Plan permits the Administrator to grant stock options, stock appreciation rights (“SARs”), performance shares,
performance units, shares of common stock, restricted stock, restricted stock units (“RSUs”), cash incentive awards, dividend
equivalent units, or any other type of award permitted under the 2023 Omnibus Plan. The Administrator may grant any type of award to
any participant it selects, but only our employees or our subsidiaries’ employees may receive grants of incentive stock options
within the meaning of Section 422 of the Internal Revenue Code. Awards may be granted alone or in addition to, in tandem with, or (subject
to the repricing prohibition described below) in substitution for any other award (or any other award granted under another plan of our
company or any affiliate, including the plan of an acquired entity).

64

Shares
Reserved Under the 2023 Omnibus Incentive Plan

The
2023 Omnibus Plan will provide that 6,500,000 shares of our common stock are reserved for issuance under the 2023 Omnibus Plan, all of
which may be issued pursuant to the exercise of incentive stock options. The number of shares available for issuance under our 2023 Omnibus
Plan